PAREXEL EXPERTS TO PRESENT ON KEY TRENDS IN LATE PHASE DEVELOPMENT AND COMPARATIVE EFFECTIVENESS RESEARCH AT ISPOR ANNUAL EUROPEAN CONGRESS
Boston, MA, October 22, 2009 – Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address key trends in late phase development and Comparative Effectiveness Research at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress, to be held from October 24 – 27, 2009 in Paris, France.
Attendees at the meeting will be able to learn more about capabilities related to these topics by visiting the PAREXEL Stands #87 and #88 in the exhibit hall. PAREXEL representatives will be in attendance to discuss expertise related to all phases of clinical development, reimbursement and market access, and medical communications. In addition, representatives from PAREXEL’s subsidiary, Perceptive Informatics, a leading eClinical solutions provider, will be present to discuss the capabilities of its eClinical Suite, including the collection of electronic patient-reported outcomes, to accelerate clinical development.
The ISPOR Annual European Congress program features the following sessions:
Sunday, October 25
• The Role of Patient Registries in Evidence Development: Similarities and Differences Between Europe and North America - Yvonne Lis, Consultant, Peri-Approval Services, PAREXEL (W6: Session I Workshop, 15:15 - 16:15)
• Trends in Comparative Effectiveness of Top 20 Highest Selling Drugs - Saurabh Aggarwal, PhD, Senior Consultant, Reimbursement and Market Access, PAREXEL Consulting (Poster Session I: PHP59, 12:00 - 19:30)
Tuesday, October 27
• Patient Registries - A Literature Review of Recently Reported Registry Based Studies - Yvonne Lis, Consultant, Peri-Approval Services, PAREXEL (Poster Session III: PMC76, 8:00 - 16:00)
For more information about PAREXEL visit www.PAREXEL.com or Stands #87 and 88. Information about the congress can be found at http://www.ispor.org.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has approximately 9,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.